|Articles|December 14, 2022
PHASTAR Joins Oncology Development Program (ODP2)
Targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets.
Advertisement
PHASTAR, has joined Lean Life Science’s Oncology Development Program (ODP2). The targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
Read more about the program
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Drug Repurposing Through AI-Driven In-Silico Clinical Trials
2
ACT Brief: FDA’s Agentic AI Rollout, Exercise Interventions for Long COVID, and Patient-Centered Evidence Beyond the Trial
3
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
4
Targeted and Strategy-Driven Clinical Development
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
